SCARB1 and cancer: Overall, as far as cancer therapeutics are concerned, whereas SR-B1 would be the first point of entry at the plasma membrane of cells, some drugs, such as topoisomerase inhibitors and transcription factors, would have to cross a second barrier, the nuclear membrane.